Open Government Portal

What health professionals need to know about HIV and AIDS, prevention, disease progression, clinical manifestations, diagnosis, treatment and surveillance.

Find information, tools and facts about symptoms, risks and how to prevent, treat and manage HIV and AIDS.

This evaluation covered the activities of the Federal Initiative (FI) to Address HIV/AIDS in Canada for the period of 2013-14 to 2017-18. FI represents an annual investment ranging from $70 to $78 million. The evaluation was undertaken in fulfillment of the requirements of the Financial Administration Act and the Treasury Board of Canada's Policy on Results (2016).

In 2016, an estimated 63,110 people were living with HIV.

A series of health-related data sets from various quantitative public opinion research studies.

The number of persons who are infected with HIV and not yet tested (i.e. are not even aware themselves that they have HIV) is impossible to know precisely. This number is estimated using statistical models and methods with data from a variety of sources.

How coronavirus infection is spread by infected people and how to help reduce your risk of infection by washing your hands and avoiding touching your eyes, nose or mouth with unwashed hands.

HIV diagnosis rates remained stable over the last decade, with some minor fluctuations.

The human immunodeficiency virus (HIV) and the human T-cell lymphotropic virus type 1 (HTLV-1) are examples of RG3 pathogens where the pathogen risk and CL assessments have been revisited by the Agency in conjunction with HIV/HTLV specialists based on current risks associated with activities involving these pathogens. It has been determined that HIV & HTLV-1 can be safely handled at CL2/CL2-Ag with specific additional operational requirements (see Section 4.0). This Biosafety Directive is intended to provide a comprehensive overview of the risk assessment outcomes, subsequent CL decisions, and considerations that have been made for those working with HIV and HTLV-1. The Biosafety Directive for HIV and HTLV-1 is to be used in conjunction with the CBSG.

The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases.